Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.

Prudden HJ, Achilles SL, Schocken C, Broutet N, Canfell K, Akaba H, Basu P, Bhatla N, Chirenje ZM, Delany-Moretlwe S, Denny L, Gamage DG, Herrero R, Hutubessy R, Villa LL, Murillo R, Schiller JT, Stanley M, Temmerman M, Zhao F, Ogilvie G, Kaslow DC, Dull P, Gottlieb SL, Therapeutic HPV Vaccine PPC Expert Consultation Group*.

Open source

DOI: 10.1016/j.vaccine.2022.08.020
Published: 2022-08-22
Container: Vaccine
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2022.08.020,
  title = {Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.},
  author = {Prudden HJ and  Achilles SL and  Schocken C and  Broutet N and  Canfell K and  Akaba H and  Basu P and  Bhatla N and  Chirenje ZM and  Delany-Moretlwe S and  Denny L and  Gamage DG and  Herrero R and  Hutubessy R and  Villa LL and  Murillo R and  Schiller JT and  Stanley M and  Temmerman M and  Zhao F and  Ogilvie G and  Kaslow DC and  Dull P and  Gottlieb SL and  Therapeutic HPV Vaccine PPC Expert Consultation Group*.},
  year = {2022},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2022.08.020},
  url = {https://doi.org/10.1016/j.vaccine.2022.08.020}
}

RIS

TY  - JOUR
TI  - Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.
AU  - Prudden HJ
AU  -  Achilles SL
AU  -  Schocken C
AU  -  Broutet N
AU  -  Canfell K
AU  -  Akaba H
AU  -  Basu P
AU  -  Bhatla N
AU  -  Chirenje ZM
AU  -  Delany-Moretlwe S
AU  -  Denny L
AU  -  Gamage DG
AU  -  Herrero R
AU  -  Hutubessy R
AU  -  Villa LL
AU  -  Murillo R
AU  -  Schiller JT
AU  -  Stanley M
AU  -  Temmerman M
AU  -  Zhao F
AU  -  Ogilvie G
AU  -  Kaslow DC
AU  -  Dull P
AU  -  Gottlieb SL
AU  -  Therapeutic HPV Vaccine PPC Expert Consultation Group*.
PY  - 2022
JO  - Vaccine
DO  - 10.1016/j.vaccine.2022.08.020
UR  - https://doi.org/10.1016/j.vaccine.2022.08.020
ER  -

APA

HJ, P., SL, A., C, S., N, B., K, C., H, A., P, B., N, B., ZM, C., S, D., L, D., DG, G., R, H., R, H., LL, V., R, M., JT, S., M, S., M, T., F, Z., G, O., DC, K., P, D., SL, G., & Group*., T. H. V. P. E. C. (2022). Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022.. Vaccine. https://doi.org/10.1016/j.vaccine.2022.08.020

Source records

europe-pmc · retrieved 2026-09-27T11:12:07.346Z